Molecular therapy of primary hyperoxaluria.

about

Recurrent primary hyperoxaluria type 2 leads to early post-transplant renal function loss: A case report.

P2860

Q52653091-F4890135-6F4B-496F-9B15-0DE95EBBF264

P2860

Molecular therapy of primary hyperoxaluria.

Item

http://www.wikidata.org/entity/Q45866877

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Molecular therapy of primary hyperoxaluria.

@en

Molecular therapy of primary hyperoxaluria.

@nl

type

Item

label

Molecular therapy of primary hyperoxaluria.

@en

Molecular therapy of primary hyperoxaluria.

@nl

prefLabel

Molecular therapy of primary hyperoxaluria.

@en

Molecular therapy of primary hyperoxaluria.

@nl

P1476

Molecular therapy of primary hyperoxaluria.

@en

P2093

Armando Torres

http://www.w3.org/2001/XMLSchema#string

Cristina Martin-Higueras

http://www.w3.org/2001/XMLSchema#string

Eduardo Salido

http://www.w3.org/2001/XMLSchema#string

P2860

Identification and characterization of HAOX1, HAOX2, and HAOX3, three human peroxisomal 2-hydroxy acid oxidases

Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1

Structure of human glycolate oxidase in complex with the inhibitor 4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1,2,3-thiadiazole

AKI transition of care: a potential opportunity to detect and prevent CKD

Primary hyperoxalurias: disorders of glyoxylate detoxification

The consensus-based approach for gene/enzyme replacement therapies and crystallization strategies: the case of human alanine-glyoxylate aminotransferase

Functional synergism between the most common polymorphism in human alanine:glyoxylate aminotransferase and four of the most common disease-causing mutations

Progress and prospects: immune responses to viral vectors

Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer

Molecular modifiers reveal a mechanism of pathological crystal growth inhibition

P2888

s10545-017-0045-3

P304

481-489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10545-017-0045-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Armando Torres

Eduardo Salido

Cristina Martin-Higueras

P577

2017-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084977412

http://www.w3.org/2001/XMLSchema#string

P698

28425073

http://www.w3.org/2001/XMLSchema#string

Molecular therapy of primary hyperoxaluria.

about

P2860

P2860

Molecular therapy of primary hyperoxaluria.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698